Olutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial

Overview of attention for article published in Neuro-Oncology, May 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#15 of 4,190)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 44 news outlets
twitter: 5 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 37 Mendeley

So far, Altmetric has seen 1 Guideline that references this research output.

SEOM-GEINO clinical guidelines for grade 2 gliomas (2023)

Clinical guideline published by Sociedad Española de Oncología Médica (SEOM) on 25 Apr 2024

The Sociedad Española de Oncología Médica (SEOM) is a leading organization in Spain dedicated to oncology. It provides comprehensive resources, including clinical guidelines, educational programs, and research support, aimed at improving cancer care and treatment outcomes for patients.

This page shows the most recent posts that mention this research output. Click here to find out how to access more activity.